Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation.

Keating SM, Taylor DL, Plant AL, Litwack ED, Kuhn P, Greenspan EJ, Hartshorn CM, Sigman CC, Kelloff GJ, Chang DD, Friberg G, Lee JSH, Kuida K.

Clin Transl Sci. 2018 May;11(3):267-276. doi: 10.1111/cts.12536. Epub 2018 Mar 2. Review.

2.

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.

Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP.

JAMA Oncol. 2017 Jul 13;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580. Epub 2017 Jul 13.

3.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

4.

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.

Grossman RL, Abel B, Angiuoli S, Barrett JC, Bassett D, Bramlett K, Blumenthal GM, Carlsson A, Cortese R, DiGiovanna J, Davis-Dusenbery B, Dittamore R, Eberhard DA, Febbo P, Fitzsimons M, Flamig Z, Godsey J, Goswami J, Gruen A, Ortuño F, Han J, Hayes D, Hicks J, Holloway D, Hovelson D, Johnson J, Juhl H, Kalamegham R, Kamal R, Kang Q, Kelloff GJ, Klozenbuecher M, Kolatkar A, Kuhn P, Langone K, Leary R, Loverso P, Manmathan H, Martin AM, Martini J, Miller D, Mitchell M, Morgan T, Mulpuri R, Nguyen T, Otto G, Pathak A, Peters E, Philip R, Posadas E, Reese D, Reese MG, Robinson D, Dei Rossi A, Sakul H, Schageman J, Singh S, Scher HI, Schmitt K, Silvestro A, Simmons J, Simmons T, Sislow J, Talasaz A, Tang P, Tewari M, Tomlins S, Toukhy H, Tseng HR, Tuck M, Tzou A, Vinson J, Wang Y, Wells W, Welsh A, Wilbanks J, Wolf J, Young L, Lee J, Leiman LC.

Clin Pharmacol Ther. 2017 May;101(5):589-592. doi: 10.1002/cpt.666. Epub 2017 Apr 12. Review.

5.

Biomarker development in the context of urologic cancers.

Kelloff GJ, Sigman CC, Scher HI.

Urol Oncol. 2015 Jun;33(6):295-301. doi: 10.1016/j.urolonc.2015.01.007. Epub 2015 Mar 5. Review.

6.

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA.

Clin Cancer Res. 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13.

7.

Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development.

Yoo SS, Jorgensen TJ, Kennedy AR, Boice JD Jr, Shapiro A, Hu TC, Moyer BR, Grace MB, Kelloff GJ, Fenech M, Prasanna PG, Coleman CN.

J Radiol Prot. 2014 Jun;34(2):R25-52. doi: 10.1088/0952-4746/34/2/R25. Epub 2014 Apr 14. Review.

PMID:
24727460
8.

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.

Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, Deverka P, Frueh FW, Jessup JM, McShane LM, Tunis SR, Sigman CC, Kelloff GJ.

Clin Cancer Res. 2014 Mar 15;20(6):1428-44. doi: 10.1158/1078-0432.CCR-13-2961.

9.

Considerations in the development of circulating tumor cell technology for clinical use.

Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ.

J Transl Med. 2012 Jul 2;10:138. doi: 10.1186/1479-5876-10-138. Review.

10.

Cancer biomarkers: selecting the right drug for the right patient.

Kelloff GJ, Sigman CC.

Nat Rev Drug Discov. 2012 Feb 10;11(3):201-14. doi: 10.1038/nrd3651. Review.

PMID:
22322254
11.

Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.

Meyskens FL Jr, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E; C-Change Chemoprevention Clinical Trials and Biomarkers Subcommittee.

Cancer Prev Res (Phila). 2011 Mar;4(3):311-23. doi: 10.1158/1940-6207.CAPR-09-0014.

12.

Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.

Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC, Aerts HJ, Bendriem B, Bendtsen C, Boellaard R, Boone JM, Cole PE, Conklin JJ, Dorfman GS, Douglas PS, Eidsaunet W, Elsinger C, Frank RA, Gatsonis C, Giger ML, Gupta SN, Gustafson D, Hoekstra OS, Jackson EF, Karam L, Kelloff GJ, Kinahan PE, McLennan G, Miller CG, Mozley PD, Muller KE, Patt R, Raunig D, Rosen M, Rupani H, Schwartz LH, Siegel BA, Sorensen AG, Wahl RL, Waterton JC, Wolf W, Zahlmann G, Zimmerman B.

Radiology. 2011 Jun;259(3):875-84. doi: 10.1148/radiol.10100800. Epub 2011 Feb 15.

13.

Challenges in clinical prostate cancer: role of imaging.

Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group.

AJR Am J Roentgenol. 2009 Jun;192(6):1455-70. doi: 10.2214/AJR.09.2579.

14.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ.

Clin Pharmacol Ther. 2009 Jul;86(1):97-100. doi: 10.1038/clpt.2009.68. Epub 2009 May 13.

PMID:
19440188
15.

Early detection of oral neoplasia: watching with new eyes.

Kelloff GJ, Sigman CC, Contag CH.

Cancer Prev Res (Phila). 2009 May;2(5):405-8. doi: 10.1158/1940-6207.CAPR-09-0064. Epub 2009 Apr 28. Review. No abstract available.

16.

Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine.

Eckelman WC, Reba RC, Kelloff GJ.

Drug Discov Today. 2008 Sep;13(17-18):748-59. doi: 10.1016/j.drudis.2008.05.009. Epub 2008 Jul 24. Review.

PMID:
18617011
17.

Regulatory and reimbursement challenges for molecular imaging.

Hoffman JM, Gambhir SS, Kelloff GJ.

Radiology. 2007 Dec;245(3):645-60.

PMID:
18024447
18.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039
19.

Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development.

Kelloff GJ, Sigman CC.

Nat Rev Cancer. 2007 Jul;7(7):508-18. Review.

PMID:
17568791
20.

FDG-PET lymphoma demonstration project invitational workshop.

Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J.

Acad Radiol. 2007 Mar;14(3):330-9.

PMID:
17307666
21.

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.

Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D.

Int J Radiat Biol. 2006 Oct;82(10):699-757. Review.

PMID:
17118889
22.

Chemoprevention strategies in the prostate: an overview.

Kelloff GJ, Higley HR, Brawer MK, Lucia MS, Sigman CC, Crawford ED.

Rev Urol. 2002 Spring;4(2):69-77.

23.

Imaging and oncologic drug development.

El-Deiry WS, Sigman CC, Kelloff GJ.

J Clin Oncol. 2006 Jul 10;24(20):3261-73. Review.

PMID:
16829650
24.

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK; AACR Task Force on Cancer Prevention.

Clin Cancer Res. 2006 Jun 15;12(12):3661-97. Review.

25.

The progress and promise of molecular imaging probes in oncologic drug development.

Kelloff GJ, Krohn KA, Larson SM, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J.

Clin Cancer Res. 2005 Nov 15;11(22):7967-85. Review.

26.

Development of cancer chemopreventive drugs based on mechanistic approaches.

Steele VE, Kelloff GJ.

Mutat Res. 2005 Dec 11;591(1-2):16-23. Epub 2005 Aug 3. Review.

PMID:
16083917
27.

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.

Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC.

Clin Cancer Res. 2005 Apr 15;11(8):2785-808. Review.

28.

New science-based endpoints to accelerate oncology drug development.

Kelloff GJ, Sigman CC.

Eur J Cancer. 2005 Mar;41(4):491-501. Epub 2005 Jan 22. Review.

PMID:
15737552
29.

N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.

Simeone AM, Deng CX, Kelloff GJ, Steele VE, Johnson MM, Tari AM.

Carcinogenesis. 2005 May;26(5):1000-7. Epub 2005 Feb 3.

PMID:
15695235
30.

Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies.

Christov KT, Moon RC, Lantvit DD, Boone CW, Kelloff GJ, Steele VE, Lubet RA, Pezzuto JM.

Eur J Cancer. 2004 Jun;40(9):1404-11.

PMID:
15177500
31.

Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.

Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV.

Clin Cancer Res. 2004 Jun 1;10(11):3927-33. Review. No abstract available.

32.

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.

Rustin GJ, Bast RC Jr, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW.

Clin Cancer Res. 2004 Jun 1;10(11):3919-26. Review. No abstract available.

33.

Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs.

Kelloff GJ, Schilsky RL, Alberts DS, Day RW, Guyton KZ, Pearce HL, Peck JC, Phillips R, Sigman CC.

Clin Cancer Res. 2004 Jun 1;10(11):3908-18. Review. No abstract available.

34.

Reanalysis of cancer drugs: old drugs, new tricks.

Vande Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ.

Clin Cancer Res. 2004 Jun 1;10(11):3897-907. Review. No abstract available.

35.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. Review. No abstract available.

36.

Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.

Kelloff GJ, Bast RC Jr, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF.

Clin Cancer Res. 2004 Jun 1;10(11):3881-4. Review. No abstract available.

37.

Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.

Sabichi AL, Xu H, Fischer S, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Clifford JL.

Clin Cancer Res. 2003 Oct 1;9(12):4606-13.

38.

Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.

Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC.

Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):593-6. No abstract available.

39.

Strategies for chemoprevention of prostate cancer.

Kelloff GJ, Lieberman R, Brawer MK, Crawford ED, Labrie F, Miller GJ, Kelloff GJ.

Prostate Cancer Prostatic Dis. 1999 Jan;2(S1):27-33.

40.

9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats.

Christov KT, Moon RC, Lantvit DD, Boone CW, Steele VE, Lubet RA, Kelloff GJ, Pezzuto JM.

Cancer Res. 2002 Sep 15;62(18):5178-82.

41.

A quantitative angiogenesis model for efficacy testing of chemopreventive agents.

Sharma S, Ghoddoussi M, Gao P, Kelloff GJ, Steele VE, Kopelovich L.

Anticancer Res. 2001 Nov-Dec;21(6A):3829-37.

PMID:
11911254
42.

Modulation of Ki67, p53 and RARbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents.

D'Ambrosio SM, Gibson-D'Ambrosio RE, Wani G, Casto B, Milo GE, Kelloff GJ, Steele VE.

Anticancer Res. 2001 Sep-Oct;21(5):3229-35.

PMID:
11848477
43.

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD.

Clin Cancer Res. 2002 Feb;8(2):314-46.

44.

Induction of atypical ductal hyperplasia in mouse mammary gland organ culture.

Mehta RG, Bhat KP, Hawthorne ME, Kopelovich L, Mehta RR, Christov K, Kelloff GJ, Steele VE, Pezzuto JM.

J Natl Cancer Inst. 2001 Jul 18;93(14):1103-6. No abstract available.

PMID:
11459872
45.

Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells.

Sun SY, Yue P, Kelloff GJ, Steele VE, Lippman SM, Hong WK, Lotan R.

Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):595-601.

46.

Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer.

Clifford JL, Sabichi AL, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Lippman SM.

Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):391-5.

47.

Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast.

Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN.

Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59.

48.

Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas.

Herzog CR, Crist KA, Sabourin CL, Kelloff GJ, Boone CW, Stoner GD, You M.

Mol Carcinog. 2001 Mar;30(3):159-68.

PMID:
11301476
49.

Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer.

Weiss HL, Urban DA, Grizzle WE, Cronin KA, Freedman LS, Kelloff GJ, Lieberman R.

Urology. 2001 Apr;57(4 Suppl 1):220-3.

PMID:
11295632
50.

Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.

Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC.

Urology. 2001 Apr;57(4 Suppl 1):46-51.

PMID:
11295594

Supplemental Content

Loading ...
Support Center